Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...
Xenon Pharmaceuticals (XENE) said Wednesday said it was set to receive a payment of $15 million from its epilepsy joint venture partner Neurocrine...
Neurocrine Biosciences (NBIX) has an average rating of outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) on Thursday reported preliminary Ingrezza drug sales of about $301 million for Q4 and about $1.1 billion for the full year...
| Address | 12780 El Camino Real San Diego, California 92130 |
| Phone | +1.858.617.7600 |
| Number of Employees | 585 |
| Recent SEC Filing | 01/12/2022 4 |
| Chief Executive Officer & Director | Kevin Charles Gorman |
| Vice President-Information Technology & Operations | Bill Wilson |
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Research Officer | Dimitri E. Grigoriadis |
| Price Open | $75.41 |
| Previous Close | $78.36 |
| 52 Week Range | $71.88 - 120.27 |
| Market Capitalization | $7.1 B |
| Shares Outstanding | 94.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 17.15 |
| Earnings per Share | $4.83 |
| Beta vs. S&P 500 | N/A |
| Revenue | $451.2 M |
| Net Profit Margin | 41.59% |
| Return on Equity | 35.89% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
